Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial

Circulation

Volumn 97, Issue 15, 1998, Pages 1446-1452

  Sacks, Frank M ^a,f   Moyé, Lemuel A ^b   Davis, Barry R ^b   Cole, Thomas G ^c   Rouleau, Jean L ^d   Nash, David T ^e   Pfeffer, Marc A ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cholesterol; Coronary disease; Drugs; Lipoproteins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK MANAGEMENT; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 0032554688     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.15.1446     Document Type: Article

References (24)

1. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 1995;76:10C-17C.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
4. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini J. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995;92:2419-2425.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Theroux P, Warnica JW, Arnold JM, Nash DT, Wun CC, Davis BR, Hawkins CM, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
6. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C-77C.
7. Rubins HB, Robins SJ, Collins C, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH, Anderson JW, Kashyap ML, Schectman G. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 1995;75:1196-1201.
8. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Lipids and lipoproteins in symptomatic coronary heart disease. Circulation. 1992;86:839-848.
9. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction of incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365-374.
10. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
11. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events Trial (CARE). Am J Cardiol. 1991;68:1436-1446.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
13. Katz MH, Hauck WW. Proportional hazards (Cox) regression. J Gen Intern Med. 1993;8:702-711.
14. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
15. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
16. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, Rossouw J, Shekelle R, Yusuf S. Report of the conference on low blood cholesterol: mortality associations. Circulation. 1992;86:1046-1060.
17. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nodeljkovic S, Nissinen A, Toshima H. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five year follow-up of the Seven Countries Study. JAMA. 1995; 274:131-136.
18. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. BMJ. 1991;303:276-282.
19. Assmann G, Schulte H. Relation of HDL cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease: the PROCAM experience. Am J Cardiol. 1992;70:733-737.
20. Goldbourt U, Yaari S. Cholesterol and coronary heart disease mortality: a 23-year follow-up study of 9902 men in Israel. Arteriosclerosis. 1990; 10:512-519.
21. Fager G, Wiklund O. Cholesterol reduction and clinical benefit: are there limits to our expectations? Arterioscler Thromb Vasc Biol. 1997;17: 3527-3533.
22. Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH. The influence of pretreatment LDL cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol. 1995;76:78C-85C.
23. Rossouw JE. Lipid lowering interventions in angiographic trials. Am J Cardiol. 1995;76:86C-92C.
24. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol. 1995;76:899-905.